Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study
Authors:
- Padraic G. O’mAlleyPOPadraic G. O’mAlley
- Bashir Al Hussein Al AwamlhBABashir Al Hussein Al Awamlh
- Guojiao WuGWGuojiao Wu
- Ian M. ThompsonITIan M. Thompson
- Martin SandaMSMartin Sanda
- Mark RubinMRMark Rubin
- John T. WeiJWJohn T. Wei
- Richard LeeRLRichard Lee
- Paul ChristosPCPaul Christos
- Christopher BarbieriCBChristopher Barbieri
- Douglas S. ScherrDSDouglas S. Scherr
- 1 July 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 198 (1) , 42-49
Abstract
To our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. Demographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network). Utility was determined by generating ROC curves and comparing AUC values for the baseline multivariable PCPT model and for models containing biomarker scores. PCA3 and T2ERG added utility for the prediction of prostate cancer and clinically significant prostate cancer when combined with the PCPT Risk Calculator. This utility was seen in nonAfrican American men only for PCA3 (AUC 0.64 increased to 0.75 for prostate cancer and to 0.69-0.77 for clinically significant prostate cancer, both p <0.001) and for T2ERG (AUC 0.64-0.74 for prostate cancer, p <0.001, and 0.69-0.73 for clinically significant prostate cancer, p = 0.029). African American men did not have an added benefit with the addition of biomarkers, including PCA3 (AUC 0.75-0.77, p = 0.64, and 0.65-0.66, p = 0.74) and T2ERG (AUC 0.75-0.74, p = 0.74, and 0.65-0.64, p = 0.88), for prostate cancer and clinically significant prostate cancer, respectively. Limitations include the small number of African American men (72). The post hoc subgroup analysis nature of the study limited findings to being hypothesis generating. As novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts.Keywords
This publication has 30 references indexed in Scilit:
- Molecular markers for cancer prognosis and treatment: Have we struck gold?Cancer Letters, 2012
- Prostate-Cancer Mortality at 11 Years of Follow-upNew England Journal of Medicine, 2012
- Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative GroupWorld Journal of Urology, 2011
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSAScience Translational Medicine, 2011
- Association of Insurance and Race/Ethnicity with Disease Severity among Men Diagnosed with Prostate Cancer, National Cancer Database 2004-2006Cancer Epidemiology, Biomarkers & Prevention, 2010
- The use of PCA3 in the diagnosis of prostate cancerNature Reviews Urology, 2009
- Generalizability of Associations from Prostate Cancer Genome-Wide Association Studies in Multiple PopulationsCancer Epidemiology, Biomarkers & Prevention, 2009
- Multiple regions within 8q24 independently affect risk for prostate cancerNature Genetics, 2007
- The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic PerformanceClinical Cancer Research, 2007
- DD3 RNA Analysis in Urine ? A New Perspective for Detecting Prostate CancerEuropean Urology, 2004